Results 151 to 160 of about 22,335 (252)
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options. [PDF]
Ren R, Liang X, Wei X.
europepmc +1 more source
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake +14 more
wiley +1 more source
Editorial: Hot topics in diabetes and steatotic liver disease. [PDF]
Stoica RA.
europepmc +1 more source
Circadian disruption via constant light induces sex‐specific remodeling of the microbiome, lipid mediators, and immune responses. Females exhibit broader gut microbiota alterations, reduced jejunal oxylipins, increased hypothalamic N‐acylethanolamines, and a more inflammatory cytokine profile. Muscle responses are sex‐ and fiber type‐dependent: females
Pejman A. Pashaki +7 more
wiley +1 more source
Association of food insecurity with metabolic dysfunction-associated steatotic liver disease by sex and race/ethnicity. [PDF]
Tao MH +7 more
europepmc +1 more source
Bringing Gene Therapy Into Real World Clinical Practice
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach +2 more
wiley +1 more source
The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease. [PDF]
Siddiqui MS +17 more
europepmc +1 more source
The gut-liver axis in progressive steatotic liver disease
The gut-liver axis regulates metabolic homeostasis, with bile acids (BAs) serving as key signalling molecules. BA dysregulation is implicated in metabolic dysfunction-associated steatotic liver disease (MASLD)and metabolic dysfunction- and alcohol-associated liver disease (MetALD), yet consistent identification of BA markers and their mechanistic roles
Louca, Panayiotis +11 more
openaire +1 more source

